Fibrocell Science (FCSC) 2.83 $FCSC
Fibrocell Science Hosting R&D Day on September 24, 2014
Business Wire - Wed Sep 10, 3:05PM CDT
Fibrocell Science, Inc. (NASDAQ:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that it will host an R&D Day in New York on September 24, 2014. Presentations by key opinion leaders will include the Company's lead orphan disease program that uses genetically-modified autologous fibroblasts--developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology--to treat recessive dystrophic epidermolysis bullosa (RDEB), a debilitating, genetic skin disease. In addition, updates will be presented on two Phase II clinical trials for azficel-T, Fibrocell's proprietary autologous fibroblast technology, for vocal cord scarring and restrictive burn scarring. Both studies leverage the Company's existing BLA for azficel-T through supplemental drug applications to develop treatments for serious scarring conditions.
Why Fibrocell Science (FCSC) Might Be a Diamond in the Rough - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 7:42AM CDT
Fibrocell Science has been witnessing a positive trend in its loss estimates front and possess a favorable Zacks Rank #2 (Buy)
Why Fibrocell Science (FCSC) Could Be a Potential Winner - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 25, 7:34AM CDT
Fibrocell Science large positive estimate revisions and impressive Zacks Rank suggest that better days may be ahead for this stock.
Fibrocell Science, Inc. to Move Stock Listing to NASDAQ
Business Wire - Mon Aug 18, 3:05PM CDT
Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on developing first-in class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that it will transfer its U.S. stock exchange listing from the NYSE MKT to The NASDAQ Capital Market. The Company expects its securities to cease trading on the NYSE MKT effective at the close of business on August 28, 2014 and to commence trading on NASDAQ on August 29, 2014 when the market opens. The company will retain its current ticker symbol, "FCSC," when trading begins on NASDAQ.
Fibrocell Science Reports Second Quarter and First Half 2014 Financial and Operating Results
Business Wire - Mon Aug 11, 7:00AM CDT
Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today reported financial results for the second quarter and first half of 2014. The company will host a conference call and webcast today at 8:30 a.m. EDT.
Fibrocell Science to Present at Wedbush 2014 Life Sciences Management Access Conference
Business Wire - Tue Aug 05, 3:05PM CDT
Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that David Pernock, chairman and chief executive officer, and Greg Weaver, senior vice president and chief financial officer, of Fibrocell Science will present at the Wedbush 2014 Life Sciences Management Access Conference at 10:20 a.m. EDT on Tuesday, August 12, 2014, in New York City. Mr. Pernock and Mr. Weaver will discuss the company's autologous fibroblast technology, its therapeutic candidates in development, and its collaboration with Intrexon Corporation (NYSE: XON) to develop genetically-modified personalized biologics.
Fibrocell Science to Report Second Quarter 2014 Financial and Operating Results, and Host Conference Call and Webcast on August 11, 2014
Business Wire - Mon Aug 04, 3:05PM CDT
Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that it will report second quarter and first half 2014 financial and operating results on August 11, 2014. David Pernock, chairman and chief executive officer of Fibrocell Science, will host the conference call and webcast at 8:30 a.m. EDT, August 11, 2014.
Epidermolysis Bullosa - Pipeline Review, H1 2014
M2 - Wed Jul 30, 3:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xjhcc9/epidermolysis) has announced the addition of the "Epidermolysis Bullosa - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Epidermolysis Bullosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Epidermolysis Bullosa - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Epidermolysis Bullosa pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - RegeneRx Biopharmaceuticals, Inc. - Fibrocell Science, Inc. - Birken AG - Scioderm, Inc. For more information visit http://www.researchandmarkets.com/research/xj...dermolysis
Fibrocell Science Takes Active Role to Support Dystrophic Epidermolysis Bullosa Patient Advocacy Group
Business Wire - Wed Jul 23, 7:05AM CDT
Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, announced today that it will present at the 2014 Patient Care Conference of the Dystrophic Epidermolysis Bullosa Research Association of America (DebRA) as part of the company's commitment to engage and support advocacy groups for patients with rare diseases. Held every other year, this educational forum brings together patients and their families to connect with one another and hear about new research for epidermolysis bullosa (EB). John Maslowski, vice president of scientific affairs at Fibrocell, will discuss the company's commitment to genetically-modified, autologous human fibroblasts for the treatment of recessive dystrophic epidermolysis bullosa, RDEB, the most severe form of dystrophic EB. This year's DebRA Patient Care Conference is scheduled for July 30 - August 2 in Nashville, Tenn.
Global Stem Cell Therapy Market 2014-2020: Treatment Mode, Therapeutic Applications, Regulatory Landscape & Pipeline Analysis
M2 - Fri Jul 11, 2:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vfm5cm/stem_cell_therapy) has announced the addition of the "Global Stem Cell Therapy Market 2014-2020: Treatment Mode, Therapeutic Applications, Regulatory Landscape & Pipeline Analysis" report to their offering. The global stem cell therapy market is estimated to grow at a lower CAGR in developed countries as compared to emerging countries such as China, India, and Korea in the forecast period (2015-2020). Factors such as increasing funding from various governments and private organizations focus on stem cell research by the growing industry, and rising global awareness about stem cell therapies through various organizations are propelling the growth of the stem cell therapy market. However, lack of required infrastructures, ethical issues related to embryonic stem cell, and the difficulties related with the preservation of stem cells are restraining the growth of this market. In this report, the global stem cell therapy market has been segmented on the basis of mode of therapy (allogeneic and autologous stem cell therapy) and therapeutic applications (eye diseases, metabolic diseases, GIT diseases, musculoskeletal disorders, immune system diseases, CNS diseases, CVS diseases, wounds and injuries, and others). The allogeneic stem cell therapy market is expected to hold the largest share of the global stem cell therapy market by 2015. This large share can be attributed to the launch of the first-in-class stem cell therapy called prochymal (Osiris Therapeutics, Inc., U.S.), for the treatment of acute graft-versus-host disease (GVHD) in children. This allogeneic therapy was approved in New Zealand and Canada, in May 2012. Additionally, allogeneic stem cell therapy market is expected to grow at a higher CAGR as compared to the autologous stem cell therapy. Factors such as wider therapeutic applications, easier production scale up, and larger number of ongoing clinical trials of allogeneic stem cell therapies compared to autologous stem cell therapies are stimulating its market growth. Major players such as Mesoblast Ltd. (Australia), Aastrom Biosciences, Inc. (U.S.), Celgene Corporation (U.S.), and StemCells, Inc. (U.S.) are adopting several growth strategies such as new product approvals, partnerships/agreements/collaborations, joint ventures, mergers, and acquisitions in order to keep pace with the evolving industry trends. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Dynamics 4 Pipeline Analysis 5 Investor Network 6 Global Stem Cell Therapy Market, By Mode Of Therapy 7 Global Stem Cell Therapy Market, By Therapeutic Applications 8 Regulatory Landscape 9 Global Stem Cell Therapy Market, By Geography 10 Competitive Landscape 11 Company Profiles - Aastrom Biosciences Inc. - Advanced Cell Technologies, Inc. - Athersys Inc. - Celgene Corporation - Cellular Dynamics International - Cytori Therapeutics, Inc. - Fibrocell Science, Inc. - Gamida Cell Ltd. - Mesoblast Ltd. - Pluristem Therapeutics Inc. - StemCells Inc. For more information visit http://www.researchandmarkets.com/research/vf...ll_therapy
FIbrocell Science Announces Exclusive Technology License Agreements with UCLA to Advance the Development of Personalized Cell Therapies
Business Wire - Tue Jun 17, 7:00AM CDT
Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, announced today that it has entered into an exclusive license agreement with The Regents of the University of California. Under the agreement, Fibrocell acquired the rights to commercially apply patented discoveries and technologies resulting from the ongoing scientific collaboration between the University of California at Los Angeles (UCLA) and Fibrocell Science.
Fibrocell Science Receives Orphan Drug Designation for Genetically-Modified Autologous Human Fibroblasts to Advance Treatment Development for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Business Wire - Fri Jun 13, 7:00AM CDT
Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its genetically-modified autologous human fibroblasts to treat dystrophic epidermolysis bullosa (DEB), a broad category of rare and severe genetic skin diseases that includes RDEB. Fibrocell is working with leading medical centers--whose research focuses on all forms of epidermolysis bullosa, including DEB and RDEB--to advance development of its lead therapeutic candidate for the most severe form of epidermolysis bullosa, RDEB.
Fibrocell Science to Present at 2nd Annual Regen Med Investor Day and BioCentury Future Leaders in the Biotech Industry Conference
Business Wire - Thu Mar 20, 4:30PM CDT
Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that Gregory Weaver, senior vice president and chief financial officer of Fibrocell Science, will present at the Alliance for Regenerative Medicine's (ARM) 2nd Annual Regen Med Investor Day at 4:00 p.m. EDT on Wednesday, March 26, 2014 at the Metropolitan Club in New York, and the BioCentury Future Leaders in the Biotech Industry conference at 10:30 a.m. EDT on Friday, March 28, 2014 at the Millennium Broadway Hotel & Conference Center in New York. Mr. Weaver will discuss the company's autologous fibroblast technology, its therapeutic candidates in development, and its collaboration with Intrexon Corporation (NYSE: XON) to develop genetically-modified personalized biologics.
Earnings Estimates Moving Higher for Fibrocell Science (FCSC): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 7:46AM CDT
Fibrocell Science (FCSC)sees solid earnings estimate revision activity, and the stock is showing decent short-term momentum as well, rising nearly 24% in the past month.
Intrexon Deal Update Overshadows Q4 Loss at Fibrocell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 9:00AM CDT
Fibrocell's deal with Intrexon holds great promise.
Fibrocell Science Reports Fourth Quarter and Full Year 2013 Financial and Operating Results
Business Wire - Mon Mar 17, 7:01AM CDT
Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today reported financial results for the fourth quarter and full year ended Dec. 31, 2013. The company will host a conference call and webcast at 8:30 a.m. EDT, today.
Egalet Appoints Timothy P. Walbert to Board of Directors
GlobeNewswire - Tue Mar 11, 7:14AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
today announced the appointment of Timothy P. Walbert, chairman, president and chief executive officer of Horizon Pharma, to its board of directors.
Fibrocell Science to Report Fourth Quarter and Full Year 2013 Financial and Operating Results, and Host Conference Call and Webcast on March 17
Business Wire - Mon Mar 10, 3:05PM CDT
Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, today announced that it will report fourth quarter and full-year 2013 financial results and provide an update on the morning of March 17, 2014. The update will include its collaboration with Intrexon Corporation (NYSE:XON). David Pernock, chairman and chief executive officer of Fibrocell, will host the conference call and webcast at 8:30 a.m. EDT, Mar. 17, 2014.
Fibrocell Science to Present at Barclays Global Healthcare Conference 2014
Business Wire - Wed Mar 05, 3:05PM CST
Fibrocell Science (NYSEMKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, today announced that David Pernock, chairman and chief executive officer of Fibrocell Science, will present at the Barclays Global Healthcare Conference 2014 at 2:30 pm EDT on Wednesday, March 12, 2014, at the Loews Hotel in Miami. Mr. Pernock will discuss the company's autologous fibroblast technology, its therapeutic candidates in development, and its collaboration with Intrexon Corporation (NYSE:XON) to develop genetically-modified personalized biologics.
Global Cell Therapy Market & Pipeline Insight Research Report
M2 - Tue Mar 04, 3:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/5kmmgq/global_cell) has announced the addition of the "Global Cell Therapy Market & Pipeline Insight" report to their offering. Research in cell therapy is transforming the future of medicine. As the life of a human being begins as a cell, these cells undergo a highly complex set of events and finally those few stems become capable of self-renewal and differentiation and develop into the specialized cells in the body. Cell therapy research also offers significant potential for restructuring the method of medical practice. Over the past 3-5 years, a more complex therapeutic modality has been is emerging as cell therapies which have been developed to treat diseases which are not amenable to treatment with more classical pharmaceutical or biopharmaceutical products. This market offers the promise of successfully regenerating damaged tissues and organs in the body by replacing the damaged tissue and/or by stimulating the body's own repair mechanisms to heal previously irreparable tissues. With their rising popularity, these therapies are becoming more cost effective and efficient. The global market for cell therapy was valued at close to USD 2.5 Billion in 2012. With continuous advances and developments in this field of medicine, the global cell therapy market is expected to grow at a high rate of 20-22% to reach approximately USD 8 Billion by 2018. Several products and technologies of cell-based therapies are in the R&D pipeline are expected to enter the market during the forecast period, thus resulting in an increased growth rate. It is most likely that the new improved technologies would revolutionize the area of bio-pharma and personalized medicine. Development of sophisticated automation devices for cell expansion and culture process for use in the treatment is one of the emerging trends of ACT market. With the cell-based therapies growing by leaps and bounds, it is expected that the future years would witness significant advancements in technology in the cell therapy market. Increasing incidence of diseases along with lack of adequate effective treatment for these diseases is most likely to drive the cell therapy technology in developed and developing nations. Among the emerging trends of the global market, the most prominent one is the development of sophisticated automation devices for cell expansion and culture process which could be used in the treatment of life threatening diseases. Global Cell Therapy Market & Pipeline Insight Report Highlights & Findings: - Introduction to Cell therapy - Global Cell Therapy Market Overview - Global Cell Therapy Market Dynamics - Cell Therapy Pipeline by Phase, Country & Target Indications - Cell Therapy Drugs in Pipeline: More Than 200 - Highest Number of Drugs in Preclinical Stage: 73 - Number of Drugs in Phase I/II Stage: 35 - Key Market: US - Majority Cell therapies For Cancer Treatment Companies Mentioned - Advanced Cell Technology - Amgen - California Stem Cell - Celgene Corporation - Cytomedix - Fibrocell Science - Genzyme - NeoStem - Novartis - Stemedica Cell Technologies For more information visit http://www.researchandmarkets.com/research/5k...lobal_cell About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Fibrocell Science Hosting R&D Day on September 24, 2014
Business Wire - Wed Sep 10, 3:05PM CDT
Fibrocell Science, Inc. (NASDAQ:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that it will host an R&D Day in New York on September 24, 2014. Presentations by key opinion leaders will include the Company's lead orphan disease program that uses genetically-modified autologous fibroblasts--developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology--to treat recessive dystrophic epidermolysis bullosa (RDEB), a debilitating, genetic skin disease. In addition, updates will be presented on two Phase II clinical trials for azficel-T, Fibrocell's proprietary autologous fibroblast technology, for vocal cord scarring and restrictive burn scarring. Both studies leverage the Company's existing BLA for azficel-T through supplemental drug applications to develop treatments for serious scarring conditions.
Why Fibrocell Science (FCSC) Might Be a Diamond in the Rough - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 7:42AM CDT
Fibrocell Science has been witnessing a positive trend in its loss estimates front and possess a favorable Zacks Rank #2 (Buy)
Why Fibrocell Science (FCSC) Could Be a Potential Winner - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 25, 7:34AM CDT
Fibrocell Science large positive estimate revisions and impressive Zacks Rank suggest that better days may be ahead for this stock.
Fibrocell Science, Inc. to Move Stock Listing to NASDAQ
Business Wire - Mon Aug 18, 3:05PM CDT
Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on developing first-in class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that it will transfer its U.S. stock exchange listing from the NYSE MKT to The NASDAQ Capital Market. The Company expects its securities to cease trading on the NYSE MKT effective at the close of business on August 28, 2014 and to commence trading on NASDAQ on August 29, 2014 when the market opens. The company will retain its current ticker symbol, "FCSC," when trading begins on NASDAQ.
Fibrocell Science Reports Second Quarter and First Half 2014 Financial and Operating Results
Business Wire - Mon Aug 11, 7:00AM CDT
Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today reported financial results for the second quarter and first half of 2014. The company will host a conference call and webcast today at 8:30 a.m. EDT.
Fibrocell Science to Present at Wedbush 2014 Life Sciences Management Access Conference
Business Wire - Tue Aug 05, 3:05PM CDT
Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that David Pernock, chairman and chief executive officer, and Greg Weaver, senior vice president and chief financial officer, of Fibrocell Science will present at the Wedbush 2014 Life Sciences Management Access Conference at 10:20 a.m. EDT on Tuesday, August 12, 2014, in New York City. Mr. Pernock and Mr. Weaver will discuss the company's autologous fibroblast technology, its therapeutic candidates in development, and its collaboration with Intrexon Corporation (NYSE: XON) to develop genetically-modified personalized biologics.
Fibrocell Science to Report Second Quarter 2014 Financial and Operating Results, and Host Conference Call and Webcast on August 11, 2014
Business Wire - Mon Aug 04, 3:05PM CDT
Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that it will report second quarter and first half 2014 financial and operating results on August 11, 2014. David Pernock, chairman and chief executive officer of Fibrocell Science, will host the conference call and webcast at 8:30 a.m. EDT, August 11, 2014.
Epidermolysis Bullosa - Pipeline Review, H1 2014
M2 - Wed Jul 30, 3:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xjhcc9/epidermolysis) has announced the addition of the "Epidermolysis Bullosa - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Epidermolysis Bullosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Epidermolysis Bullosa - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Epidermolysis Bullosa pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - RegeneRx Biopharmaceuticals, Inc. - Fibrocell Science, Inc. - Birken AG - Scioderm, Inc. For more information visit http://www.researchandmarkets.com/research/xj...dermolysis
Fibrocell Science Takes Active Role to Support Dystrophic Epidermolysis Bullosa Patient Advocacy Group
Business Wire - Wed Jul 23, 7:05AM CDT
Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, announced today that it will present at the 2014 Patient Care Conference of the Dystrophic Epidermolysis Bullosa Research Association of America (DebRA) as part of the company's commitment to engage and support advocacy groups for patients with rare diseases. Held every other year, this educational forum brings together patients and their families to connect with one another and hear about new research for epidermolysis bullosa (EB). John Maslowski, vice president of scientific affairs at Fibrocell, will discuss the company's commitment to genetically-modified, autologous human fibroblasts for the treatment of recessive dystrophic epidermolysis bullosa, RDEB, the most severe form of dystrophic EB. This year's DebRA Patient Care Conference is scheduled for July 30 - August 2 in Nashville, Tenn.
Global Stem Cell Therapy Market 2014-2020: Treatment Mode, Therapeutic Applications, Regulatory Landscape & Pipeline Analysis
M2 - Fri Jul 11, 2:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vfm5cm/stem_cell_therapy) has announced the addition of the "Global Stem Cell Therapy Market 2014-2020: Treatment Mode, Therapeutic Applications, Regulatory Landscape & Pipeline Analysis" report to their offering. The global stem cell therapy market is estimated to grow at a lower CAGR in developed countries as compared to emerging countries such as China, India, and Korea in the forecast period (2015-2020). Factors such as increasing funding from various governments and private organizations focus on stem cell research by the growing industry, and rising global awareness about stem cell therapies through various organizations are propelling the growth of the stem cell therapy market. However, lack of required infrastructures, ethical issues related to embryonic stem cell, and the difficulties related with the preservation of stem cells are restraining the growth of this market. In this report, the global stem cell therapy market has been segmented on the basis of mode of therapy (allogeneic and autologous stem cell therapy) and therapeutic applications (eye diseases, metabolic diseases, GIT diseases, musculoskeletal disorders, immune system diseases, CNS diseases, CVS diseases, wounds and injuries, and others). The allogeneic stem cell therapy market is expected to hold the largest share of the global stem cell therapy market by 2015. This large share can be attributed to the launch of the first-in-class stem cell therapy called prochymal (Osiris Therapeutics, Inc., U.S.), for the treatment of acute graft-versus-host disease (GVHD) in children. This allogeneic therapy was approved in New Zealand and Canada, in May 2012. Additionally, allogeneic stem cell therapy market is expected to grow at a higher CAGR as compared to the autologous stem cell therapy. Factors such as wider therapeutic applications, easier production scale up, and larger number of ongoing clinical trials of allogeneic stem cell therapies compared to autologous stem cell therapies are stimulating its market growth. Major players such as Mesoblast Ltd. (Australia), Aastrom Biosciences, Inc. (U.S.), Celgene Corporation (U.S.), and StemCells, Inc. (U.S.) are adopting several growth strategies such as new product approvals, partnerships/agreements/collaborations, joint ventures, mergers, and acquisitions in order to keep pace with the evolving industry trends. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Dynamics 4 Pipeline Analysis 5 Investor Network 6 Global Stem Cell Therapy Market, By Mode Of Therapy 7 Global Stem Cell Therapy Market, By Therapeutic Applications 8 Regulatory Landscape 9 Global Stem Cell Therapy Market, By Geography 10 Competitive Landscape 11 Company Profiles - Aastrom Biosciences Inc. - Advanced Cell Technologies, Inc. - Athersys Inc. - Celgene Corporation - Cellular Dynamics International - Cytori Therapeutics, Inc. - Fibrocell Science, Inc. - Gamida Cell Ltd. - Mesoblast Ltd. - Pluristem Therapeutics Inc. - StemCells Inc. For more information visit http://www.researchandmarkets.com/research/vf...ll_therapy
FIbrocell Science Announces Exclusive Technology License Agreements with UCLA to Advance the Development of Personalized Cell Therapies
Business Wire - Tue Jun 17, 7:00AM CDT
Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, announced today that it has entered into an exclusive license agreement with The Regents of the University of California. Under the agreement, Fibrocell acquired the rights to commercially apply patented discoveries and technologies resulting from the ongoing scientific collaboration between the University of California at Los Angeles (UCLA) and Fibrocell Science.
Fibrocell Science Receives Orphan Drug Designation for Genetically-Modified Autologous Human Fibroblasts to Advance Treatment Development for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Business Wire - Fri Jun 13, 7:00AM CDT
Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its genetically-modified autologous human fibroblasts to treat dystrophic epidermolysis bullosa (DEB), a broad category of rare and severe genetic skin diseases that includes RDEB. Fibrocell is working with leading medical centers--whose research focuses on all forms of epidermolysis bullosa, including DEB and RDEB--to advance development of its lead therapeutic candidate for the most severe form of epidermolysis bullosa, RDEB.
Fibrocell Science to Present at 2nd Annual Regen Med Investor Day and BioCentury Future Leaders in the Biotech Industry Conference
Business Wire - Thu Mar 20, 4:30PM CDT
Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that Gregory Weaver, senior vice president and chief financial officer of Fibrocell Science, will present at the Alliance for Regenerative Medicine's (ARM) 2nd Annual Regen Med Investor Day at 4:00 p.m. EDT on Wednesday, March 26, 2014 at the Metropolitan Club in New York, and the BioCentury Future Leaders in the Biotech Industry conference at 10:30 a.m. EDT on Friday, March 28, 2014 at the Millennium Broadway Hotel & Conference Center in New York. Mr. Weaver will discuss the company's autologous fibroblast technology, its therapeutic candidates in development, and its collaboration with Intrexon Corporation (NYSE: XON) to develop genetically-modified personalized biologics.
Earnings Estimates Moving Higher for Fibrocell Science (FCSC): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 7:46AM CDT
Fibrocell Science (FCSC)sees solid earnings estimate revision activity, and the stock is showing decent short-term momentum as well, rising nearly 24% in the past month.
Intrexon Deal Update Overshadows Q4 Loss at Fibrocell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 9:00AM CDT
Fibrocell's deal with Intrexon holds great promise.
Fibrocell Science Reports Fourth Quarter and Full Year 2013 Financial and Operating Results
Business Wire - Mon Mar 17, 7:01AM CDT
Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today reported financial results for the fourth quarter and full year ended Dec. 31, 2013. The company will host a conference call and webcast at 8:30 a.m. EDT, today.
Egalet Appoints Timothy P. Walbert to Board of Directors
GlobeNewswire - Tue Mar 11, 7:14AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
today announced the appointment of Timothy P. Walbert, chairman, president and chief executive officer of Horizon Pharma, to its board of directors. Fibrocell Science to Report Fourth Quarter and Full Year 2013 Financial and Operating Results, and Host Conference Call and Webcast on March 17
Business Wire - Mon Mar 10, 3:05PM CDT
Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, today announced that it will report fourth quarter and full-year 2013 financial results and provide an update on the morning of March 17, 2014. The update will include its collaboration with Intrexon Corporation (NYSE:XON). David Pernock, chairman and chief executive officer of Fibrocell, will host the conference call and webcast at 8:30 a.m. EDT, Mar. 17, 2014.
Fibrocell Science to Present at Barclays Global Healthcare Conference 2014
Business Wire - Wed Mar 05, 3:05PM CST
Fibrocell Science (NYSEMKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for skin diseases and conditions with high unmet medical needs, today announced that David Pernock, chairman and chief executive officer of Fibrocell Science, will present at the Barclays Global Healthcare Conference 2014 at 2:30 pm EDT on Wednesday, March 12, 2014, at the Loews Hotel in Miami. Mr. Pernock will discuss the company's autologous fibroblast technology, its therapeutic candidates in development, and its collaboration with Intrexon Corporation (NYSE:XON) to develop genetically-modified personalized biologics.
Global Cell Therapy Market & Pipeline Insight Research Report
M2 - Tue Mar 04, 3:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/5kmmgq/global_cell) has announced the addition of the "Global Cell Therapy Market & Pipeline Insight" report to their offering. Research in cell therapy is transforming the future of medicine. As the life of a human being begins as a cell, these cells undergo a highly complex set of events and finally those few stems become capable of self-renewal and differentiation and develop into the specialized cells in the body. Cell therapy research also offers significant potential for restructuring the method of medical practice. Over the past 3-5 years, a more complex therapeutic modality has been is emerging as cell therapies which have been developed to treat diseases which are not amenable to treatment with more classical pharmaceutical or biopharmaceutical products. This market offers the promise of successfully regenerating damaged tissues and organs in the body by replacing the damaged tissue and/or by stimulating the body's own repair mechanisms to heal previously irreparable tissues. With their rising popularity, these therapies are becoming more cost effective and efficient. The global market for cell therapy was valued at close to USD 2.5 Billion in 2012. With continuous advances and developments in this field of medicine, the global cell therapy market is expected to grow at a high rate of 20-22% to reach approximately USD 8 Billion by 2018. Several products and technologies of cell-based therapies are in the R&D pipeline are expected to enter the market during the forecast period, thus resulting in an increased growth rate. It is most likely that the new improved technologies would revolutionize the area of bio-pharma and personalized medicine. Development of sophisticated automation devices for cell expansion and culture process for use in the treatment is one of the emerging trends of ACT market. With the cell-based therapies growing by leaps and bounds, it is expected that the future years would witness significant advancements in technology in the cell therapy market. Increasing incidence of diseases along with lack of adequate effective treatment for these diseases is most likely to drive the cell therapy technology in developed and developing nations. Among the emerging trends of the global market, the most prominent one is the development of sophisticated automation devices for cell expansion and culture process which could be used in the treatment of life threatening diseases. Global Cell Therapy Market & Pipeline Insight Report Highlights & Findings: - Introduction to Cell therapy - Global Cell Therapy Market Overview - Global Cell Therapy Market Dynamics - Cell Therapy Pipeline by Phase, Country & Target Indications - Cell Therapy Drugs in Pipeline: More Than 200 - Highest Number of Drugs in Preclinical Stage: 73 - Number of Drugs in Phase I/II Stage: 35 - Key Market: US - Majority Cell therapies For Cancer Treatment Companies Mentioned - Advanced Cell Technology - Amgen - California Stem Cell - Celgene Corporation - Cytomedix - Fibrocell Science - Genzyme - NeoStem - Novartis - Stemedica Cell Technologies For more information visit http://www.researchandmarkets.com/research/5k...lobal_cell About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
